US Capitol Capsule: In belt-tightened FY14, FDA, Alzheimer's research do well
This article was originally published in Scrip
Executive Summary
While the budget agreement reached last month by Democrats and Republicans means more belt-tightening for much of the federal government, the FDA did remarkably well in the amount of dollars Congress is appropriating to the agency for fiscal year 2014, the Alliance for a Stronger FDA said last week.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.